Journal of Research in Ayurvedic Sciences

Register      Login

Table of Content

2017 | July-September | Volume 1 | Issue 3

RESEARCH ARTICLE

Om Raj Sharma, Prashant Shinde, Kavita Vyas

Clinical Observation of Haridrakhanda in the Management of Sheetapitta with respect to Urticaria: A Retrospective Cohort

[Year:2017] [Month:July-September] [Volume:1] [Number:3] [Pages:5] [Pages No:131 - 135]

PDF  |  DOI: 10.5005/jp-journals-10064-0014  |  Open Access |  How to cite  | 

Abstract

Introduction: In the present era, one inevitably meets with various causes of Dhatu-daurbalya (disturbed immune system), which lead to various allergic diseases like urticaria— a type I hypersensitivity reaction that can be compared with Sheetapitta mentioned in Ayurveda. Although the disease is not life-threatening, it makes the patient troubled due to severe itching and its long-lasting tendency. Aims and objectives: To observe safety and efficacy of Haridrakhanda in the patients suffering from Sheetapitta (urticaria) in the clinical setting. Materials and methods: An observational retrospective cohort design was adopted for the study. Patients of either sex, suffering from urticaria, of age between 18 and 70 years, were selected from the outpatient department (OPD) of Regional Ayurveda Research Institute for Nutritional Disorders (RARIND), Central Council of Research in Ayurvedic Sciences (CCRAS), Mandi, Himachal Pradesh, India, from March 2013 to June 2014. The patients who were treated with Haridrakhanda in the dose of 3 gm twice a day with milk for 14 days and who have shown 100% compliance of medicine were only considered for study. Following Ayurveda clinical symptoms of Sheetapitta were observed: Varati Dashta Samsthana Shotha (inflammation rash, like an insect bite), Kandubahulya (severe itching), Todabahulya (severe pricking pain), Raga (redness of skin), Vidaha (burning sensation), Chhardi (vomiting), and Jwara (fever) with grading of 0 (absent), 1 (mild), 2 (moderate), and 3 (severe). Results: Neither any concomitant medication was used nor was any adverse effect reported or noticed during the study. At the end of day 14, all 39 patients experienced improvement, maximum in Toda (pain) followed by Kandu (itching) and Varati Dashta Samsthana Shotha (swelling). Statistically significant improvement was found in all signs and symptoms (p < 0.001). Conclusion: Haridrakhanda was found safe and effective in the management of Sheetapitta. This study may be considered as a primary evidence for further studies on large sample size to consolidate the results.

RESEARCH ARTICLE

Punendu Panda, Laxman W Burke, Surendra K Sharma, Surendra K Sharma, Krishna Kumari, Om Raj Sharma, Rinku Tomar, Gurucharan Bhuyan, Rakesh K Rana

Clinical Safety of Selected Ayurvedic Formulations in Management of Irritable Bowel Syndrome

[Year:2017] [Month:July-September] [Volume:1] [Number:3] [Pages:6] [Pages No:136 - 141]

PDF  |  DOI: 10.5005/jp-journals-10064-0015  |  Open Access |  How to cite  | 

Abstract

Introduction: Irritable bowel syndrome (IBS) is a part of the larger group of functional gastrointestinal (GI) disorders that despite differences in location and symptom patterns share common features with regard to their motor and sensory physiology and central nervous system relationships. It generates a significant health care burden and can severely impair quality of life. It is characterized by symptoms of abdominal pain and discomfort that is associated with disturbed defecation. Ayurveda compares the symptoms of IBS with some of the diseases like Grahani, Kaphaja Pravahika, Shokaja Atisara, Bhayaja Atisara, etc. Bilvadi Leha and Kutajarishta are two common Ayurvedic formulations that are currently used for the management of such diseases. However, the safety of these drugs was not evaluated until now. Objective: Analysis of clinical safety and efficacy outcomes of Bilvadi Leha and Kutajarishta in IBS generated through multicenter open-label clinical studies at different CCRAS centers. Materials and methods: Analysis of data collected from two different clinical studies was critically evaluated. Safety assessments were done through analyzing liver function tests (LFTs), alanine aminotransferase, aspartate aminotransferase, serum alkaline phosphatase, serum protein, albumin, globulin, and bilirubin, and kidney function tests (KFTs) before and after the trial period. Paired sample t-test was used for comparison. A p-value < 0.05 was considered significant. Drug compliance and adverse drug reaction/adverse events, if any, were noted. Conclusion: The analysis of two different clinical studies clearly reveals that Bilvadi Leha and Kutajarishta are clinically safe, effective, and tolerable.

RESEARCH ARTICLE

Bhagwan S Sharma, Puthenveettil KS Nair, Rajesh Sannd, Varanasi Subhose, Rajesh Kumari, Rakesh K Rana

Clinical Safety of Selected Ayurvedic Formulations in Obesity and Dyslipidemia

[Year:2017] [Month:July-September] [Volume:1] [Number:3] [Pages:8] [Pages No:142 - 149]

PDF  |  DOI: 10.5005/jp-journals-10064-0016  |  Open Access |  How to cite  | 

Abstract

Introduction: Obesity is a condition of abnormal or excessive fatness, and dyslipidemia is a condition with abnormal raised levels of any one or all lipids in the blood. Ayurveda compares signs and symptoms of obesity and dyslipidemia with the disease Sthaulya/Medoroga. Vyoshadi Guggulu and Haritaki Churna are the most commonly used medicines in the management of Sthaulya. However, the safety of these drugs was not evaluated until now through clinical trials. Objective: The objective of this study was to assess clinical safety of Vyoshadi Guggulu and Haritaki Churna in the management of obesity (Sthaulya) and dyslipidemia. Materials and methods: A prospective, open-label multicentric study was carried out at peripheral institutes of the Central Council for Research in Ayurvedic Sciences (CCRAS). Total 306 patients satisfying selection criteria were randomly selected from the outpatient department of respective centers and were administered Vyoshadi Guggulu (3 tablets of 500 mg) and Haritaki Churana (3 gm twice daily) in case of obesity, and Vyoshadi Guggulu (2 tablets of 500 mg thrice in a day) and Haritaki Churana (3 gm twice daily in cases of dyslipidemia) with lukewarm water for 12 weeks. So, the daily intake of the medicine was similar in all these cases. Hematological parameters, viz., lipid profile, and safety parameters were assessed at baseline and at the end of 12 weeks. Paired sample t-test was applied to compare the changes. Results: At the end of 12 weeks, compared with baseline, no statistically significant difference was observed in liver function tests (LFTs) and kidney function tests (KFTs) in the subjects. Conclusion: The findings clearly indicate that Vyoshadi Guggulu and Haritaki Churna are clinically safe and tolerable in subjects with obesity and dyslipidemia belonging to different age groups, gender, geographical area, and different Prakrti.

RESEARCH ARTICLE

Manohar Gundeti, Govind Reddy, anjay K Giri, Rakesh K Rana, Bharti , Madan M Padhi

Clinical Safety of Selected Ayurvedic Formulations in Osteopenia/Osteoporosis

[Year:2017] [Month:July-September] [Volume:1] [Number:3] [Pages:7] [Pages No:150 - 156]

PDF  |  DOI: 10.5005/jp-journals-10064-0017  |  Open Access |  How to cite  | 

Abstract

Introduction: Osteopenia/osteoporosis is a condition characterized by decrease in bone mineral density. It is a major public health problem especially for women in India. The clinical picture of osteopenia/osteoporosis is similar to the condition of Asthidhatukshaya described in Ayurveda which is characterized by the loss of saarata of Asthi dhatu leading to increased predisposition to other bone-related pathologies. Laksha Guggulu, Mukta-Shukti Pishti, Ashwagandha Churna, and Pravala Pishti are some of the most common medicines used in the management of osteopenia/osteoporosis. However, safety data are not collected on these formulations. Objective: To critically analyze and present clinical safety of classical Ayurvedic formulations, viz., Laksha Guggulu, Mukta-Shukti Pishti, Ashwagandha Churna, and Pravala Pishti in osteopenia/osteoporosis, through multicenter open-label studies at different Central Council for Research in Ayurvedic Sciences (CCRAS) centers. Materials and methods: Data were collected from two different clinical studies executed in peripheral institutes of CCRAS and critically analyzed to assess the safety of four formulations: Laksha Guggulu, Mukta-Shukti Pishti, Ashwagandha Churna, and Pravala Pishti in osteopenia/osteoporosis. Safety assessments were done through liver function tests [LFTs; serum glutamate pyruvate transaminase (SGPT), serum glutamate oxaloacetic transaminase (SGOT), alkaline phosphatase (ALP), serum protein, albumin, globulin, and bilirubin] and kidney function tests (KFTs; serum urea and serum creatinine) before and after the trial period. Drug compliance and adverse drug reaction/adverse events, if any, were noted. Conclusion: The finding in the two clinical studies indicated that Laksha Guggulu, Mukta-Shukti Pishti, Ashwagandha Churna, and Pravala Pishti are clinically safe, effective, and tolerable as participants belonging to different age groups, gender, geographical areas, and having different prakriti responded well to the trial medications without any adverse reactions or adverse events.

RESEARCH ARTICLE

Aaditya B Shah, Anup Thakar

Management of Premature Ejaculation (Shukragata vata) with Erandamoola basti and Vanari kalpa: A Clinical Study

[Year:2017] [Month:July-September] [Volume:1] [Number:3] [Pages:8] [Pages No:157 - 164]

PDF  |  DOI: 10.5005/jp-journals-10064-0018  |  Open Access |  How to cite  | 

Abstract

Introduction: Premature ejaculation (PE) is one of the most common sexual dysfunctions in men. Premature ejaculation is characterized with a short ejaculatory latency time, lack of ejaculatory control, decreased satisfaction with sexual intercourse causing interpersonal distress, negative impact on man\'s selfesteem, reduced sexual function, and reduced quality of life. In Ayurveda, the problem is discussed under Shukragata vata. Functional approximation Shukra and Vata are quite evident in Ayurvedic principles. Erandamoola is described as the best Vrishya and Vatahara in Charaka Samhita, and Vanari gutika is mentioned for treatment of PE in Bhavprakash Samhita. Objective: To evaluate the efficacy of Erandamoola basti and Vanari kalpa (granules) in the management of PE. Materials and methods: Forty-five patients with PE were treated with Vanari kalpa granules for 2 months with milk (group II), Erandamoola basti for 16 days followed by Vanari kalpa granules for 2 months with milk (group III), and placebo control with wheat granules for 2 months with milk (group I). Psychological counseling was given to the patients in all the three groups Results: Patients treated with Erandamoola basti and Vanari kalpa showed significant results against placebo in all the parameters, namely intravaginal ejaculation latency time (IELT), voluntary control over ejaculation, patient\'s and partner\'s satisfaction, and performance anxiety. Conclusion: The overall effect of therapy was higher in group III (Erandamoola basti followed by Vanari kalpa granules) with a better percentage of complete remission and marked improvement followed by groups II and I.

RESEARCH ARTICLE

Bharti , Neera Vyas

Development of Standardized Prakriti Assessment Tool: An Overview of Ongoing CCRAS Initiatives

[Year:2017] [Month:July-September] [Volume:1] [Number:3] [Pages:44] [Pages No:165 - 208]

PDF  |  DOI: 10.5005/jp-journals-10064-0019  |  Open Access |  How to cite  | 

Abstract

Introduction: Prakriti is an important basic concept of Ayurveda that describes the constitution of an individual in relation to one\'s physical, physiological, psychological, and behavioral characters and is an integral constituent of Ayurvedic diagnosis, treatment, and disease prognosis. The description for Prakriti assessment in Ayurvedic classics is mostly subjective and the translations and interpretations made on the subject are grossly dissimilar. Objective: The work of development of a Prakriti Assessment Scale with reliability, rationality, validity, and reproducibility for universal acceptance has been undertaken by the Central Council for Research in Ayurvedic Sciences (CCRAS), New Delhi, India, an apex organization for research in Ayurveda. Materials and methods: The designing of the Prakriti Assessment Scale has been done following Ayurvedic classics and consulting various subject experts in the following steps, viz.: (i) Development of a comprehensive questionnaire for assessment of Prakriti, (ii) development of a user manual containing standard operating procedures (SOPs) for capturing predictors, (iii) double-blinded validation of the questionnaire to see interrater agreement. Results: The Prakriti Assessment Scale has been designed based on standard classical texts of Ayurveda through various consultative expert group meets. The Scale captures various predictors/determinants for Prakriti assessment with the maximum possible rationality and objectivity. Further, this Scale has been subjected to clinical validation at 10 centers (n = 500) across the country. It may undergo further reductions and refinement to make it more comprehensive for clinical use. Conclusion: A comprehensive Prakriti Assessment Scale based on Ayurvedic texts has been developed and subjected to clinical validation.

REVIEW ARTICLE

Bhagwan S Sharma, Madan M Sharma, Rakesh K Rana, SK Vedi

Health Care seeking Trends in Ayurveda Clinical Research Facilities: A Central Council for Research in Ayurvedic Sciences Standpoint

[Year:2017] [Month:July-September] [Volume:1] [Number:3] [Pages:8] [Pages No:209 - 216]

PDF  |  DOI: 10.5005/jp-journals-10064-0020  |  Open Access |  How to cite  | 

Abstract

Background: The CCRAS carries out its research programs through its 30 peripheral institutes with the headquarters in New Delhi. Presently, 24 clinical units are providing outpatient services in addition to clinical research. Aim: To understand the health care seeking trends among the patients attending Central Council for Research in Ayurvedic Sciences (CCRAS) clinical research establishments from 1991 to 2012. Results: The annual reports of CCRAS from 1991 to 2012 were analyzed. A total of 107 diseases were reported in the source document, which were grouped broadly into 26 clinical categories. It was observed that out of 107 diagnosed diseases/ conditions, maximum were related to digestive system followed by nervous system, integumentary system, and urogenital system. Out of total 2,386,471 new patients, maximum number of patients were suffering from osteoarthritis, followed by neurological diseases, skin diseases, cough, pyrexia, hyperacidity, rhinitis, lower backache, abdominal colic, and dyspnea. Conclusion: Period-wise analysis of attendance of the patients to the CCRAS clinical units during the reporting period showed that there was improvement in the health care seeking behavior toward Ayurveda, which is indicated by an increase in the number of outpatient department (OPD) patients in the subsequent 5/6 years. Clinical significance: Over the years, the number of health care seekers for Ayurveda has been rapidly increasing nationally and internationally. Scientific base of Ayurveda is also getting upgraded through research. Need of the hour is to further strengthen our health care delivery system to cater to the needy population, where Ayurveda can largely contribute.

SHORT COMMUNICATION

Vinod K Lavaniya, T Saket Ram

National AYUSH Morbidity and Standardized Terminology Portal: A Short Appraisal

[Year:2017] [Month:July-September] [Volume:1] [Number:3] [Pages:4] [Pages No:217 - 220]

PDF  |  DOI: 10.5005/jp-journals-10064-0021  |  Open Access |  How to cite  | 

Abstract

The National AYUSH Morbidity and Standardized Terminology Portal (NAMSTP) is a web-based portal exclusively dedicated to the centralized collection of morbidity statistics of various health care provider institutions under all AYUSH systems spread over the country. The portal was developed and is being maintained by the Central Council for Research in Ayurvedic Sciences (CCRAS), the apex body for research in Ayurvedic Sciences, Ministry of AYUSH, Government of India. This portal was formally launched by Shri Narendra Modi, the Hon’ble prime minister of India, on the occasion of 2nd Ayurveda Day (October 17, 2017). This portal has the potential to revolutionize morbidity statistics data collection and may have a huge impact on the future policy-making decision by bringing to light the contributions of various AYUSH systems in the health care delivery system of the country. The key features of the portal include the Morbidity Codes and Standardized Terminologies of all the AYUSH systems for unambiguous reporting, electronic data submission through individual institution login ids, and also an integrated electronic health records (EHR) system for detailed data collection for individual institutions.